Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate
Eloxx Pharmaceuticals, Inc. reported Schedule 13G filings showing Samsara BioCapital and its affiliates each hold 201,793 shares, about 5.0% of Eloxx common stock. Dr. Srinivas Akkaraju reports 403,586 shares, 9.99%, based on 4,036,314 shares outstanding as of June 10, 2026. Pre-funded warrants include a 9.99% beneficial ownership blocker.
How this was made
The 30-second read
Why it matters
The key new information is the disclosed beneficial ownership level (up to 9.99%) and the structure (pre-funded warrants subject to a blocker), which can matter for control thresholds and future reporting/voting dynamics.
Market read
Traders may monitor for follow-on governance or financing catalysts, but the article itself is primarily a regulatory ownership disclosure with no operational update.
What to watch
The article does not disclose the stake’s cost basis, intent (active vs passive), or any upcoming corporate actions; without those, price reaction may be muted.
Background
The piece summarizes Schedule 13G beneficial ownership filings for Eloxx Pharmaceuticals by Samsara BioCapital-related entities and Srinivas Akkaraju, including pre-funded warrants and a 9.99% beneficial ownership blocker.
Ticker impact
Samsara BioCapital affiliates and Srinivas Akkaraju filed Schedule 13G showing beneficial ownership up to 9.99% in Eloxx Pharmaceuticals.
Likely limited near-term impact unless follow-on actions (board, financing, tender) emerge; watch for sentiment drift around ownership/control.
The article is a Schedule 13G beneficial ownership update with no stated operational catalyst, but the 9.99% level and use of a beneficial ownership blocker are control-relevant signals.
Market effects
For small-cap biotech, near-10% stake disclosures can influence how investors price governance and capital-raising optionality, but no sector-wide signal is provided here.
None indicated.
None indicated.
Counterpoint
A 13G at 9.99% with a beneficial ownership blocker may indicate a deliberate passive positioning rather than an activist push, limiting any immediate fundamental impact.
Key entities
- issuerEloxx Pharmaceuticals, Inc.
US-listed company whose common stock beneficial ownership was disclosed via Schedule 13G.
- investor_affiliateSamsara BioCapital, L.P.
Filed Schedule 13G reporting 201,793 shares (5.0%) beneficial ownership, with shared voting/dispositive power.
- investorSrinivas Akkaraju
Filed Schedule 13G reporting 403,586 shares (9.99%) beneficial ownership, including pre-funded warrants subject to a 9.99% blocker.
